Treatment with Sunitinib Enabled Complete Resection of Massive Lymphadenopathy not Previously Amenable to Excision in a Patient with Renal Cell Carcinoma. - Archive ouverte HAL Access content directly
Journal Articles European Urology Year : 2009

Treatment with Sunitinib Enabled Complete Resection of Massive Lymphadenopathy not Previously Amenable to Excision in a Patient with Renal Cell Carcinoma.

(1, 2) , (3) , (1) , (4) , (1) , (5)
1
2
3
4
5

Abstract

We present a case of previously unresectable lymphadenopathy in a patient with renal cell carcinoma treated with sunitinib. Complete resection of a 15-cm left renal cell carcinoma was initially impossible due to massive retroperitoneal disease and encasement of the great vessels and mesenteric vessels. Residual retroperitoneal disease from a radical nephrectomy was treated with the oral, multitargeted receptor tyrosine kinase inhibitor, sunitinib. Tumour shrinkage following five cycles of treatment allowed uncomplicated complete resection of the lymphadenopathy. Follow-up after 6 mo showed no evidence of disease recurrence.
Not file

Dates and versions

inserm-00325659 , version 1 (29-09-2008)

Identifiers

Cite

Jean-Jacques Patard, Rodolphe Thuret, Avakian Raffi, Brigitte Laguerre, Karim Bensalah, et al.. Treatment with Sunitinib Enabled Complete Resection of Massive Lymphadenopathy not Previously Amenable to Excision in a Patient with Renal Cell Carcinoma.. European Urology, 2009, 55 (1), pp.237-239. ⟨10.1016/j.eururo.2008.09.006⟩. ⟨inserm-00325659⟩
78 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More